LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

College of American Pathologists Releases New Proficiency Testing Program for Detection of SARS CoV-2

By LabMedica International staff writers
Posted on 11 Apr 2020
Print article
Illustration
Illustration
The College of American Pathologists {(CAP) Northfield, IL, USA) has responded to the global coronavirus disease (COVID-19) pandemic by releasing a new proficiency testing (PT) program for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). PT is used to gauge the performance of individual laboratories for specific tests and monitors continuing performance while comparing performance with other laboratories.

The CAP is an organization of board-certified pathologists and a leading provider of laboratory accreditation and proficiency testing programs that serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. The CAP offers the most comprehensive PT programs that CAP members, along with other scientists, scientifically develop and validate. More than 22,000 laboratories across the world are enrolled in the CAP’s PT programs.

The Microbiology Committee members piloted the new program with a set of laboratories prior to making it available, allowing committee members and CAP staff to verify specimen performance across the multiple methods and testing platforms. Specifically, the program is for the detection of SARS-CoV-2 by nucleic acid amplification testing. Further, it provides samples that are non-infectious and target consensus gene regions N, E, RdRp, S, and ORF1a, as well as allows laboratories to assess their entire workflow from nucleic acid extraction through detection.

“In the midst of the enormous pressure laboratories are facing, along with everyone working in health care during the COVID-19 crisis, laboratories are seeking to measure their performance when testing for the disease,” said Raouf Nakhleh, MD, FCAP, chair of the CAP’s Council on Scientific Affairs. “The CAP’s Microbiology Committee quickly came together to develop this high-quality program.”

Related Links:
College of American Pathologists

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.